Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Supressão Induzida da Atividade Plaquetária na Gestão da Hemorragia Subaracnoideia Aneurismática-2 (iSPASM-2) (iSPASM-2)

2 de novembro de 2026 atualizado por: Dr David Hasan, M.D.

Supressão Induzida da Atividade Plaquetária na Gestão de Hemorragia Subaracnoideia Aneurismática-2

An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.

Visão geral do estudo

Status

Ainda não está recrutando

Descrição detalhada

This is an exploratory, two-center, randomized, double-blinded study. The primary objective is to determine the maximum tolerated dosage (MTD) of tirofiban in the context of patients with aSAH status post-endovascular coiling. The dosage regimen of tirofiban will be 0.10µg/kg/min (actual weight) within 48 hours of aneurysm securing and within 72 hours of ictus.

The study will involve a dose escalation stage and a cohort expansion stage. During the dosage-escalation stage, the intervention doses include continuous intravenous (IV) tirofiban or IV placebo for 1 day, 3 days, 5 days, or 7 days. Dose-escalation will follow the time-to-event Bayesian Optimal Intervention (TITE-BOIN) design. Unlike the majority of existing phase I designs, which require suspending the accrual after treating each cohort of patients, the TITE-BOIN design allows for real-time dose assignment decisions for new patients while the toxicity data are still pending for some patients under treatment. This shortens the trial duration and reduces the logistical difficulties caused by frequent suspensions of accrual. For parallel comparison under real-world conditions, patients will be randomly assigned to tirofiban and placebo in a 2:1 ratio in the dose escalation stage. The data from the placebo patients will not be analyzed to inform dose escalation but included in the final analysis upon study completion. Upon the completion of the dose escalation stage, the MTD will be selected using isotonic regression. MTD will be selected as the dosage for which the isotonic estimate of the toxicity rate is closest to the target dosage-limiting toxicity rate (30%). If there is a tie, we will select the higher dosage level when the isotonic estimate is lower than the target toxicity rate, and we will select the lower dosage level when the isotonic estimate is greater than or equal to the target toxicity rate.

During the cohort expansion stage, patients will be randomized to tirofiban at MTD and placebo at the corresponding dosage level to achieve balanced sample sizes (30 tirofiban at MTD and 30 placebo for any infusion duration, combined from both phases) across the two groups. The analysis of the exploratory endpoints will be performed on the tirofiban patients at MTD and placebo patients with any infusion duration.

An interim pharmacokinetic (PK) analysis will be performed after 10 evaluable patients are treated with tirofiban to determine possible dose modification. At the completion of the study, PK and pharmacodynamic (PD) analysis will be conducted using all evaluable patients treated with tirofiban to determine whether augmented renal clearance in aSAH interacts with the pharmacokinetics and pharmacodynamics of tirofiban.

Tipo de estudo

Intervencional

Inscrição (Estimado)

82

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Duke University Health System
        • Contato:
        • Contato:
        • Investigador principal:
          • Emad Hasan, MD
        • Investigador principal:
          • Brian Mac Grory, MD
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • University of Texas Health Sciences Center
        • Contato:
        • Investigador principal:
          • Spiros Blackburn, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 85 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion:

  • Age 18-85
  • Baseline Modified Rankin Scale (mRS) 0-3 (pre-SAH)
  • SAH attributed to ruptured cerebral aneurysm
  • Admission Computed Tomography (CT) scan shows Modified Fisher grade 1-4 due to aSAH primarily in the supratentorial space
  • World Federation of Neurosurgical Societies (WFNS) scale grade ≤4 at randomization
  • Onset of symptoms of aSAH (ictus) occurred <72 hours prior to presentation
  • If External Ventricular Drain (EVD) placed, placement is ≥12 hours prior to enrollment
  • All aneurysm(s) suspected to be responsible for the hemorrhage must be secured via Endovascular Coil Embolization with a post-embolization Raymond-Roy Score of 1 (Complete) or 2 (Residual Neck) prior to enrollment
  • Participant can be randomized within 48 hours of aneurysm treatment
  • Participant or participant's legally-authorized representative (LAR) has provided documented informed consent

Exclusion:

  • Angio-negative SAH, defined as a SAH with a digital subtraction angiogram that does not show an intracranial aneurysm

  • Surgical clipping prior of the ruptured aneurysm or any non-ruptured aneurysm on the same admission to enrollment

  • Remaining untreated aneurysm(s) that could reasonably be considered a possible alternate cause of the aSAH based on the observed bleeding pattern

  • Uncontrollable hypertension (>180 systolic and/or >110 diastolic) that is not correctable prior to enrollment

  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure, or severe physical trauma within the previous month (30 days)

  • A medical diagnosis that requires continuous use of aspirin, clopidogrel, ticagrelor, or tirofiban during the study drug infusion

  • New parenchymal hemorrhage or new infarction larger than 15 cubic centimeters (cc) in volume by CT

  • Thrombolytic therapy within 24 hours prior to enrollment (alteplase, tenecteplase, or urokinase)

  • Previous intracranial hemorrhage, intracranial neoplasm, subarachnoid hemorrhage, or arterial-venous malformation

  • Thrombocytopenia (platelet count <100,000/microliter (µL) assuming clumping is ruled out

  • Allergy or intolerance to tirofiban

  • Pregnant or lactating

  • Chronic kidney disease with creatinine clearance (CrCl ≤ 30 milliliters per minute [ml/min]) or acute kidney injury (AKI) at study screening. AKI is defined as:

    i) Increase in serum creatinine by 0.3 milligrams per deciliter (mg/dL) or more (26.5 micromoles per liter [μmol/L] or more) within 48 hour period; OR ii) Increase in serum creatinine to 1.5 times or more than the baseline of the prior 7 day period; OR iii) Urine volume less than 0.5 ml/kg/hour for at least 6 hours

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Tirofiban

Continuous IV infusion of tirofiban for 1, 3, 5, or 7 days post-endovascular coiling.

IV infusion at 0.10 microgram/kilogram/minute (mcg/kg/min) for 1 day, 3 days, 5 days, or 7 days according to the dose escalation procedure.

Outros nomes:
  • Aggrastat®
Comparador de Placebo: Placebo

Continuous IV infusion of saline placebo for 1, 3, 5, or 7 days post-endovascular coiling.

IV infusion at the same infusion duration as the study drug; same adjustments

Outros nomes:
  • Solução salina normal

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Tirofiban dosage-limiting toxicity (DLT)
Prazo: Within 14 days post-randomization

Presence of any of the following: any intracranial hemorrhage, major extracranial hemorrhage (defined as clinically overt bleeding leading to death; OR clinically overt bleeding causing a reduction in hemoglobin of ≥2g/dl; OR clinically overt bleeding necessitating transfusion of ≥2 units of packed red cells or whole blood; OR clinically overt bleeding in a critical area or organ other than the intracranial compartment (including intraspinal, intraocular, pericardial, intra-articular, retroperitoneal, intramuscular [with compartment syndrome])), thrombocytopenia, or serious adverse event (SAE) due to tirofiban.

Within 14 days post-randomization

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Parâmetros farmacocinéticos - depuração total (Cltot)
Prazo: Até 7 horas após a interrupção do medicamento
Até 7 horas após a interrupção do medicamento
Parâmetros farmacocinéticos - Volume de distribuição (Vd)
Prazo: Até 7 horas após a descontinuação do medicamento
Até 7 horas após a descontinuação do medicamento
Pharmacokinetic parameters - Maximum (peak) plasma concentration (Cmax)
Prazo: Up to 7 hours after drug discontinuation

Highest concentration of tirofiban in the blood after a dose is administered

Up to 7 hours after drug discontinuation
Pharmacokinetic parameters - Minimum (trough) plasma concentration (Cmin)
Prazo: Up to 7 hours after drug discontinuation

Lowest observed concentration of tirofiban in the blood after a dose is administered

Up to 7 hours after drug discontinuation
Pharmacokinetic parameters - Average Plasma Concentration (Cavg)
Prazo: Up to 7 hours after drug discontinuation

Average tirofiban concentration in the blood at steady state

Up to 7 hours after drug discontinuation
Pharmacokinetic parameters - Area Under the Concentration (AUC)Time Curve
Prazo: Up to 7 hours after drug discontinuation

Area under the curve from time 0 extrapolated to infinite time

Up to 7 hours after drug discontinuation
Pharmacodynamic parameters - adenosine diphosphate (ADP)
Prazo: Baseline, 2, 6, and every 24 hours and at drug cessation

The percent inhibition of ADP-induced platelet aggregation

Baseline, 2, 6, and every 24 hours and at drug cessation

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Delayed cerebral ischemia (DCI) or death without DCI
Prazo: Within 14 days post-randomization

This is the primary exploratory efficacy outcome, which is a composite binary outcome. DCI is defined as any of the following: a. Focal neurological impairment, b. decrease of at least 2 points on the Glasgow coma scale and/or c. cerebral infarction present on final CT or MRI, which was not present on a CT or MRI between 24-48 hours post-endovascular therapy and not attributable to other causes.

Within 14 days post-randomization
Cerebral vasospasm
Prazo: Within 14 days post-randomization or until discharge from the index admission, which occurred later

Cerebral vasospasm requires confirmation of vasospasm on either CTA or DSA confirming mild vasospasm (decrease in vessel diameter by ≤25% of normal artery diameter), moderate vasospasm (decrease in vessel diameter by >25 to ≤50% of normal diameter but cerebral vasospasm), or severe vasospasm (decrease in vessel diameter by >50% of normal vessel diameter)

Within 14 days post-randomization or until discharge from the index admission, which occurred later
Mortality
Prazo: 3 and 6 months post-randomization

Death of any cause

3 and 6 months post-randomization
Total number of days in the ICU for the index admission
Prazo: Up to 6 months post-randomization

Total number of days from ICU admission to ICU discharge during the index hospitalization

Up to 6 months post-randomization
Total hospital stay length for the index admission
Prazo: Up to 6 months post-randomization

Total number of days from admission to discharge during the index admission

Up to 6 months post-randomization
Modified Rankin Scale (mRS)
Prazo: 3 and 6 months post-randomization

It is a clinician-reported measure of global disability, widely applied for evaluating stroke patient outcomes and as an endpoint in randomized clinical trials. It is a single-item 7-point scale with a range of 0 (no symptoms at all) to 6 (death), with higher scores indicating greater disability.

The elements of the mRS are as follows: (1) no symptoms at all; (2) no significant disability, but there may be slight symptoms such as weakness or numbness; (3) slight disability, but able to carry out daily activities independently; (4) moderate disability, requiring some help with daily activities; (5) moderately severe disability, requiring assistance with most daily activities; (6) severe disability, bedridden and requiring constant nursing care; and (7) death.

3 and 6 months post-randomization
Return to work
Prazo: 3 and 6 months post-randomization

Returned to prior level of responsibilities at work

3 and 6 months post-randomization
Lawton Instrumental Activities of Daily Living (Lawton IADL)
Prazo: 3 and 6 months post-randomization

It is an instrument to assess independent living skills among older adults, and can be used in community or hospital settings. There are 8 domains of function measured with the scale: (1) using the telephone; (2) shopping; (3) preparing food; (4) housekeeping; (5) doing laundry; (6) using transportation; (7) handling medications; (8) handling finances.

Women are scored on all 8 areas of function; historically, for men, the areas of food preparation, housekeeping, and laundering are excluded. Individuals are scored according to their highest level of functioning in that category. A summary score ranges from 0 (low function, dependent) to 8 (high function, independent) for women, and 0 through 5 for men.

3 and 6 months post-randomization
Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS)
Prazo: 3 and 6 months post-randomization

It is a 6-item scale to evaluate the overall satisfaction with facets of life relevant to people with traumatic brain injury. The area covered by the questionnaire includes physical condition, cognition, emotions, function in daily life, personal and social life, and current situation and future prospects.

Responses to each item were scored 1 ('Not at all') to 5 ('Very'), and the sum of all items was converted arithmetically to a percentage scale, with 0 representing the lowest possible (health-related quality of life (HRQoL) on the questionnaire and 100 the best possible HRQoL.

3 and 6 months post-randomization
Glasgow Outcome Scale-Extended (GOS-E)
Prazo: 3 and 6 months post-randomization

It is used to assess global outcomes in persons with brain injury, by categorizing global function using an 8-point ordinal scale that focuses on disability and functioning in daily life. The scales are: 1. Dead, 2. Vegetative State, 3. Lower Severe Disability (SD), 4. Upper SD, 5. Lower Moderate Disability (MD), 6. Upper MD, 7. Lower Good Recovery (GR), 8. Upper GR

3 and 6 months post-randomization
PROMIS-29+2
Prazo: 3 and 6 months post-randomization

The Patient-Reported Outcomes Measurement Information System® (PROMIS) is a flexible set of tools designed to measure self-reported physical, mental, and social health and wellbeing. PROMIS-29+2 is a collection of 4-item Likert-item short forms assessing the following domains:

  1. Physical function
  2. Anxiety
  3. Depression
  4. Fatigue
  5. Sleep disturbance
  6. Ability to participate in social roles and activities
  7. Pain interference
  8. Cognitive Function - Abilities (2 items)
  9. Pain intensity (single item)

Norm-based scores will be calculated for each domain on the PROMIS measures, so that a score of 50 represents the mean or average of the reference population. A score of 60 means that the person is one standard deviation above the reference population (standard deviation = 10). For PROMIS measures, higher scores equal more of the concept being measured (e.g., more Fatigue, more Physical Function).

3 and 6 months post-randomization
Montreal Cognitive Assessment (MoCA)
Prazo: 3 and 6 months post-randomization

It is a 30-point test to assess people for dementia. The MoCA evaluates different types of cognitive abilities, including orientation, short-term memory / delayed recall, executive function / visuospatial ability, language ability, abstraction, animal naming, attention, and clock-drawing. Scores range from 0 to 30, with a score of 26 or higher considered normal.

3 and 6 months post-randomization

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Emad Hasan, MD, Duke University
  • Investigador principal: Brian Mac Grory, MD, Duke University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

5 de dezembro de 2026

Conclusão Primária (Estimado)

5 de maio de 2029

Conclusão do estudo (Estimado)

5 de maio de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

10 de março de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de março de 2026

Primeira postagem (Real)

25 de março de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

4 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever